Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | BTN3A1 | O00481 | 6/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22393558 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9BTN3A1RIPK1DOT1L | |
| SCHEMBL23047641 | 0.93 | CYP3A4 (0.37) | CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL22392915 | 0.91 | BTN3A1 (0.37) | CYP3A4CYP2C9BTN3A1RIPK1DOT1L | |
| SCHEMBL24058364 | 0.91 | CYP3A4 (0.36) | CYP3A4CYP2C9BTN3A1RIPK1DOT1L | |
| SCHEMBL22355553 | 0.90 | CYP3A4 (0.36) | CYP3A4CYP2C9BTN3A1RIPK1DOT1L | |
| SCHEMBL22393557 | 0.90 | CYP3A4 (0.36) | CYP3A4CYP2C9BTN3A1RIPK1DOT1L | |
| SCHEMBL22355532 | 0.89 | BTN3A1 (0.34) | CYP3A4CYP2C9BTN3A1RIPK1DOT1L | |
| SCHEMBL23047652 | 0.88 | RIPK1 (0.33) | CYP3A4CYP2C9BTN3A1RIPK1DOT1L | |
| SCHEMBL26294375 | 0.87 | CYP3A4 (0.34) | CYP3A4CYP2C9BTN3A1RIPK1DOT1L | |
| SCHEMBL16769314 | 0.85 | CYP3A4 (0.49) | CYP3A4CYP2C9BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149049-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200277321-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277321-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | PNP, RNGTT, NT5C3B | CYP3A4 573/4885CYP2C9 401/4885BTN3A1 4231/4885 |
| US-11149049-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, TYMP, SLC29A1 | CYP3A4 600/4885CYP2C9 483/4885BTN3A1 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.